| Anaesthesiology | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | A Randomized, Double- blind placebo controlled, phase-2b study to assess the safety and efficacy effects of Art-123 on subjects with Sepsis and Disseminated Intravascular Coagulation | Dr. Suresh G Nair | Artisan Pharma |
| 2008 | Postgraduate Diploma in Clinical Research | Dr. Shanti Nair | Pfizer Limited |
| Asram Project | |||
| Year | Project Title | PI | Funding Agency |
| 2007 | Patient Monitoring Service | Surplus fund | |
| Biochemistry | |||
| Year | Project Title | PI | Funding Agency |
| 2008 | Clinical Biomedical and molecular Genetics profile of organic Acidurians | Dr. D M Vasudevan | I.C.M. R. Fellowship: Mr.Narayanan |
| Mechanisms of probiotic lactic acid bacteria in suppression of colon tumor and modulation of inflammatory responses | Dr. D M Vasudevan | I.C.M.R. Fellowship: Smt. Parvathy Varma | |
| 2005 | Effect of ethnol on functional & Structural aspects of liver | Dr. D M Vasudevan | D.S.T. Kerala |
| Biotechnology | |||
| Year | Project Title | PI | Funding Agency |
| 2006 | The role of Lactic acid Bacteria and their metabolites inhibition of Colon Cancer | Dr. Seema Nair | D.S.T.New Delhi |
| Cardiology | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | RELY-ABLE “Long Term Multicenter Extension Of Dabigatran Treatment In Patients With Atrial Fibrillation Who Completed The RELY Trial And Cluster Randomised Trial To Access The Effect Of A Knowledge Translation Intervention On Patient Outcomes | Dr. K.K.Haridas | Boehringer Ingelheim Korea Ltd |
| The Balance study Treatment of Hyponatremia Based on Lixivation in NYHA class III/IV cardiac Patient Evaluation | Dr. Vijayakumar | Cardiolune Biophama,LLC. | |
| 2008 | International multicentre randomized double blind study to compare the overall mortality in acutely ill patients with Enoxaparin versus placebo in addition to Graduated Elastic Stockings | Dr. Prakash Kamath | Aventis Pharma |
| Impact of Virgin Coconut Oil as a cooking medium on cardiovascular risk factors and clinical outcomes in patients with coronary artery disease receiving standard medical care; randomized single blind case control study with polyunsaturated sunflower oil. | Dr. K.K.Haridas | Coconut Development Board | |
| Effects of ivabradine on cardio Vascular events in patients with moderate to severe chronic heart failure and left ventricular systolicfunction. A three year randomized dauble blind placebo controlled international multicentre study. | Dr. Prakash Kamath | George Institute for health India, Hydrabad IRIS-France | |
| 2007 | Randomized Double blind parallel group Phase 3, Efficacy and safety,of AZD6140 compares with do PIdogrel for prevention of vascular events in patients with Non ST/STE ACS D5130c05262-PLATO study |
Dr. K.K.Haridas | Astra Zeneca Pharma India Ltd |
| A randomized double blind controlled trial of the efficacy and safety of the POLYCAP factor | Dr. Haridas | Cadila Pharmaceuiticals India Pvt Lts | |
| Randomized multinational daubleblind study comparing a high loading dose regimen of Clo PIdogrel versus standard dose in patients with unstable angina or non ST segment evaluation myocardial infraction managed with an early invasive Strategy Current |
Dr. Haridas | Sanofi Aventis Research & Development | |
| Early Glycoprotein Iib/IIIa Inhibition in Non-DT-segment Elevation Acute Coronary syndrome: A randomized,Placebo controlled Trial evaluating the Clinical Benefits of Early front-loaded Eptifibatide in the treatment of patients with Non-ST-segment Evaluation | Dr. K.K.Haridas | Schering- Plough Research Institute Millennium Pharmaceuticals | |
| CARDIO HEART-2D | Dr. Prakash Kamath | Trnsfer from Origin A/C | |
| 2006 | Randomised Evaluation of long term anticoagulent theraphy RELY-compairing the efficacy and safety of two blinded doses of elabigation etexilate with cepan label .warfaien for the prevention of stroke and systemic embolism in patients with non-vascular atr | Dr. K.K.Haridas | Bachringer Ingetherin |
| TAXUS OLYM PIA -global TAXUS liberate Registry Progra me to support world wide commercialisation-inter continental launch face device.TAXUS+M Liberte-SR-paclitaxil Eluting Coronary Stent System |
Dr. K.K.Haridas | Boston Scientific | |
| STITCH-Surgical Treatment for Ischemic Heart failure | Dr. Prakash Kamath | Clinic Rx Research | |
| Cardiovascular disease surveillance among the Adivasi Population | Dr. K.K.Haridas | I.C.M.R. | |
| Role of medium chain fatty acids of coconut oil in atherosclerosis | Dr. Prakash Kamath | KSCSTE | |
| FREEDOM TRIAL | Dr. K.K.Haridas | National Heart Lung and Blood Institute | |
| SE PIA ACSI/ TIMI 42 |
Dr. K.K.Haridas | Sanofi Synthelabo India Ltd | |
| 2005 | Poise study | Dr. K.K.Haridas | Astra Siniea |
| Centre for Digital Health | |||
| Year | Project Title | PI | Funding Agency |
| 2007 | Impact Telemedicine influencing rural health outcomes | Dr. Ajith N Babu | I.C.M.R |
| 2006 | Digital health at every doorstep-Integrated High Band Width Wirless communication Networks | Dr. Ajith N Babu | Media Lab Asia |
| Community Medicine / Dentistry | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | Knowledge altitudes and practices of Health Care Ethics Postgraduate students in Kerala | Dr. Chandrashekhar J | Internal (Department)/Funding Institutional |
| CVTS | |||
| Year | Project Title | PI | Funding Agency |
| 2008 | CABG OFF or ON Pump Revascularisation Study (Coronary Study) | Dr. Shiv K Nair | Canadian Institute of Health Research |
| 2005 | RSD-1235 Study | Dr. Shiv K Nair | Cardiome pharma |
| Dental College | |||
| Year | Project Title | PI | Funding Agency |
| 2007 | Oral manifestations in inflammatory Bowel Disease | Dr. Alexander | Internal (Department)/Funding Institutional |
| Dermatology | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | Randomized Double Blind place bo controlled parallel design ,multisite clinical study to evaluate the bioequivalence of calcipotriene cream 0.005% (Glenmark Generics ltd ) to dovonex ( Calcipotriene cream ) 0.005% ( Leo Pharma) in patients with moderate t | Dr. Feroze Kaliyadan | Glenmark Generics Ltd |
| 2008 | A phase I/II Dose Ranging study to evaluate the safety and efficacy anti- CD 6 monoclonal antibody (TI h Mab) in patients with active psoriasis. | Dr. Feroze Kaliyadan | Clinigene International Ltd |
| A Multicenter, Double- blind, Randomized, Parallel- group, and placebo controlled study to determine the clinical bioequivalence of a generic clorimazole 1% and Betamethasone Dipro PIonate 0.05% To PIcal Cream and the reference listed Lotrisone® (Clotrimazo | Dr. Feroze Kaliyadan | Glenmark Generics Ltd | |
| Incorporation of digital technology in dermatology teaching evaluation of effectiveness. | Dr. Feroze Kaliyadan | No Funding Required | |
| Endocrinology | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | This is a parallelarm, randomized, 16-week, double-blind, placebo-controlled Phase 2 study of LY 2189265 in patients with type2 Diabetes Mellitus who have discontinued Metformin monotherapy or have not been treated with anti hyperglycemic medications | Dr. Harish Kumar | Eli Lilly & Company |
| Safety and efficacy of Exenatide Once Weekly Injection versas Metformin,Dipeptidy 1,Pepetidase-4,Inhibitor or Thiazolidinedione as Monotherapy in Drug Naïve Patients with Type2 Diabetes | Dr. Harish Kumar | Eli Lilly & Company | |
| A randomized open label, cross over ,experimental study to evaluate the physical effects of different types of cooking Oils on glucose and li PId metabolism in healthy humen subjects | Dr. Baiju Krishnan | Internal (Department)/Funding Institutional | |
| A Phase 2 ,Randomized ,Double Blind ,Placebo And active comparator controlled study to evaluate the safety and efficiancy of MBX 102/JNJ 39659100 in patients with type 2 diabetes mellitus with inadequate glycemic control on metform in monotherapy | Dr. Harish Kumar | Metabolex Inc USA | |
| 2008 | A Randomised, Double blind, active controlled parallel group efficacy and safety study of BI 1356 (0.5 mg, administered orally once daily) compared to glime PIride ( 1 to 4 kg once daily) over two years, in type 2 diabetics patients with insufficient glyc | Dr. Harish Kumar | Bachringer Ingetherin |
| A multicentre Randomized Double blind Placebo controlled Comparative Parallel group Phase-II Clinical Trial | Dr. Ajith Kumar Varma | Centaur Pharmacuticals | |
| Development and testing new dynamically moulding foot wear for diabetic patients | Dr. Ajith Kumar Varma | D.B.T., NewDelhi | |
| Effect of metformin HCl in combination with colesevelam HCl, compared to metformin HCl alone, as initial therapy in orags- naïve subjects with Type2 Diabetes mellitus, and the effects of colesevelam, HCl on the li PId profile in subjects with pre- diabetes | Dr. Unnikrishnan | Daiichi Sankyo Pharma Development | |
| A randomized dauble blind placebo and active comparative controlled parallel group study of the efficacy and safety of Rivoglitazone as monotheraphy treatment of type 2 Diabetes mellitus with optional 26 weeks.Active comparator controlled extension period | Dr. Harish Kumar | Daiichi Sankyo Pharma Development | |
| A prospective randomized trialcompairing insulin lispro protamine suspension to Insulin Glargine in patients with type 2 diabetes on anti hyperglycemic medications | Dr. Harish Kumar | Eli Lilly & Company | |
| Treat to target comparison of two Basal Insulin Analoga (Insulin Lispro Protamine suspension and Insulin Determir in basal therapy for patients with type 2 Diabetes mellitus | Dr. Harish Kumar | Eli Lilly & Company | |
| A study on effectiveness of three different steroid dosing regimen in classical salt wasting congenital adrenal hyperplasia | Dr. Prem Kumar (DNB Student) | Endo Research Fund | |
| A randomized double blind placebo controlled parallel group study to determine whether in patients with type 2 diabetes at high risk for cardiovascular and renal events Aliskiren on top of conventional treatment reduces cardiovascular and renal morbidity | Dr. Unnikrishnan | NOVARTIS | |
| A 16 week randomized open labeled four armed treat to target parallel group trial comparing SIBA D once daily SIBA E once daily,SIBA D Monday Wednesday and Friday and Insulin Glargine once daily,all in combination with metformin in subjects with type 2 di | Dr. Harish Kumar | Novo Nordisk India Private Limited | |
| 2007 | AGI-1067 As a Novel Anti Diabetic Agent Evaluation Study | Dr. Unnikrishnan | AtheroGenics Inc |
| An open label multi-center randomised parallel group study comparing the efficacy and safety of Insulin VIAJECTTM and regular human insulin in patients with type 1 Diabetes Mellitus (VIAject-06) | Dr. Harish Kumar | Biodel | |
| An open label multi-center randomised parallel group study comparing the efficacy and safety of Insulin VIAJECTTM and regular human insulin in patients with type 2 Diabetes Mellitus (VIAject-08) | Dr. Harish Kumar | Biodel | |
| A Multicentre ,Randomized,Double-Blind Placebo-controlled phase 3 trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotheraphy with Titration in subjects with type 2 Diabetes who have inadequate Fglycemic Control with Diet and Exe | Dr. Harish Kumar | Bristol Myers Squibb Pharmasuitical Research Institute | |
| A Randomized, Double-blind, Placebo and Active Comparator-controlled, Parallel-group Study of the Efficacy and safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus | Dr. Harish Kumar | Daiichi Sankyo Pharma Development | |
| A phase 3,Open label Crossover study to Evaluate the efficacy and safety of Human Insulin inhalation Powder (HIIP) compared with once daily insulin Glargine in Insulin Native Patients with type 2 Diabetes Mellitus on Oral Agents | Dr. Harish Kumar | Eli Lilly & Company | |
| Prevelance of Fungal Infection in Web-Space Toe nail and deep tissue of diabetic foot wounds and the role of Systemic Anti-fungal agents in diabetic foot wound healing | Dr. Harish Kumar | Endo Research Fund | |
| A pre-screening Initiative to Assess HbAic Value in Patients with type 2 Mellitus and determine Eligibility for a Phase Iib Clinical study with GSK 189075 | Dr. Harish Kumar | Glaxo Smithkline | |
| A multicentre Randomized Double blind study to determine the efficacy and safety of the Addition of SYR322 25 mg versus dose Titration from 30 mg to 45 mg of ACTOS® PIoglitazone HCI in subjects with type 2 Diabetes Mellitus Who have inadequate Control on |
Dr. Harish Kumar | Takeda Global Resarch &Development centre Inc. | |
| A 24 week, Randomized,Dauble blind Placebo Controlled,Multicenters study of the safety and efficacy of PPM-204 in subjects with type-2 Diabetes. | Dr. A.G.Unnikrishnan | Wyeth Research Division | |
| 2006 | A Phase 3 Open label parallel group study to evaluate the Efficacy of Preprandial Human Insulin Inhalation powder HIIP Compared to Preprandial Injectable insulin in patients with Type 1 diabetes Mellitus -IDAV | Dr. Harish Kumar | Eli Lilly & Company |
| Hyperglycemia and its effect after a cute myocardial on cardiovascular outcomes in patientswith type2 diabetes. | Dr. Harish Kumar | Eli Lilly & Company | |
| IDAH- Study of the efficacy and safety of human insulin inhalation powder in patients with type I Diabetes Mellitus | Dr. Harish Kumar | Eli Lilly & Company | |
| IDAS-Study to evaluate the safety&efficacy of human insulin inhalation powder compared to injuctable insulin in patients with diabetes and COPD or Asthama | Dr. Harish Kumar | Eli Lilly & Company | |
| The effect of IAM technequeon stress modulated changes in neuro endocrine immuno adaptive mechanisms | Ms.Vandana | from surplus fund | |
| Liraglutide Effect and Action in Diabetes (LEAD-2) | Dr. Harish Kumar | Novo Nordisk India Private Limited | |
| Effect of endothelin receptor antagonist avosentan ontime to daubling of serum creatinine and stage renal disease or death in patients with type 2 diabetic nephropathy-AVOSETAN | Dr. Harish Kumar | Speedel Pharma Ltd | |
| Diabetes control using indiageneo develeped insulin pump in controlling blood sugar of diabetes PIgs | Dr. Harish Kumar | TIFAC CORE ,DST, N.Delhi | |
| 2005 | Development of appropriate prevention and intervention strategies for non-commentable nutritional related disorders among women in post-reproductive period | Dr. V.UshaMenon | D.S.T.New Delhi |
| 2004 | Effectof Arzoxifence on vertebral Fraction incidence and on invarsive brest cancer incidence GENERATION | Dr. Harish Kumar | Eli Lilly & Company |
| 2003 | ORGIN Study | Dr. Harish Kumar | Sanofi Aventis Research & Devolopment |
| 2002 | ADEPS-Amrita Diabetic andEndo-crine genepopulation survey | Dr. Harish Kumar | Eli Lilly & Company |
| 2001 | GeNesis Study | Dr. Harish Kumar | Eli Lilly & Company |
| ENT | |||
| Year | Project Title | PI | Funding Agency |
| 2008 | Efficacy and safety study of the antihistamine V0114CP 2.5 mg in the treatment of perinnial allergic Rhinitis. Randomized, double blind, three arm parallel, group study including placebo and active control arm (levocetirizine 5 mg) | Dr. Indhudharan | Chiltern, Navkar Chambers, ‘B’ Wing 4th Floor, Andheri, Kurla Road, Andheri (E), Mumbai- 400059. |
| Active controlled trial of the safety and Tolerability of MP 29-02 in subjects with chronic allergic or nonallergic Rhintis | Dr. Indhudharan | Medpointc Pharmaceuticals | |
| 2007 | Correlation between pre-operative and post operative computerized tomography scan(CT Scan) scores and symptomatic improvement in patients with Sino nasal polyps undergoing endoscopic sinus surgery | Dr. Indhudharan | Surplus fund |
| Gastro Surgery | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | A Multinational ,multicenter randomised double bliend study comparing the efficacy and safety of AVE 5026 with enoxaparion for the prevention of Venous Thrombocmbolism (VTE) in patients undergoing Major abdomineal Surgery | Dr. Puneet Dhar | Sanofi-Aventis Research & Development |
| Gastroentrology | |||
| Year | Project Title | PI | Funding Agency |
| 2008 | A phase III randomized,multi-centre,dauble blind,parallel group,active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (QD) with Asacol 1.6g/day twice daily (BID) in the maintenance of remission in patients | Dr. V. Balakrishnan | Shire Pharmacuitical development Ltd |
| A multicentre randomized double blind placebocontrolled dose ranging study to acess the safety and efficacy of TZP-101 when administered as a 30 miniutes I.V infusion to subjects with severe gastroparesis due to diabetes mellitus | Dr. Balakrishnan | Tranzyme Pharma,Inc | |
| 2007 | A Randomized, Double blind, Placebo-Controlled Evaluation of the Safety,Efficacy, and Pharmacokinectics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis-BSX-002. | Dr. Shine Sadasivan | Cerimon Pharmaceuticals |
| A Randomized, Double blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinectics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis- BSX-001. | Dr. Shine Sadasivan | Cerimon Pharmaceuticals | |
| Improvement of S&T infrastructure in Universities and Higher Educational Institution (FIST) Grant | Dr. Narayanan | D.S.T.New Delhi | |
| 2005 | Metabolic Study-Amino acid deficiency in tropical pancreatitis | Dr. Balakrishnan | D.S.T.Kerala |
| General Medicine | |||
| Year | Project Title | PI | Funding Agency |
| 2008 | Erythrocyte Trans Ketolase (ETK) As An Index For Thiamine Deficiancy | Dr. R.N. Sharma | Internal (Department)/Funding Institutional |
| GI Surgery | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | Hepatic strategies clinico- pathological and radiological correlation study | Dr. Datta Ram (DNB Student) | From GI Surgery |
| A prospective multicentre ,double blind ,randmized,comparative study to estimate the safety tolerability and efficacy of NXL104/ceftazidime plus metronidazole Vs meropenem in the treatment of complicated intra -abdominal infections (cIAI) in hospitalize | Dr. Puneet Dhar | Novexel.S.A.Pare Biocitech 102 | |
| A randomized, double blind, multicentric, placebo controlled, single dose, phase II study assessing the safety and efficacy of intramuscular EX vivo cultured adult allogenic mesenchymal stem cells in patients with critical limb ischemia (CLI) | Dr. Sudhindra | Stempeutics Research Pvt. Ltd | |
| 2008 | A Phase III double blind randomized study to evaluate the safety and efficacy of BAL 8557 versus a cuspafungin followed by vorilanazole Regimen in the treatment of candida infections | Dr. Puneet Dhar | Basilea Pharmacuitca Ltd |
| A Phase II study Nedjuvant Chemotheraphy followed by surgery in locally Advanced gastricCancers | Dr. Puneet Dhar | Institutional study | |
| A randomized study of of the efficacy and safety of OncoGelTM treatment as an adjunctive therapy to systematic chemotherapy and concurrent external beam radiation prior to surgery in subjects with localized or loco- regional esophageal cancer. | Dr. Puneet Dhar | Protherics Inc | |
| Protocol TAR-ORI-SD001 titled Nuvocid TM(Coritavancin) at single or infrequent doses for the treatment of complicated skin and skin structure infections | Dr. Puneet Dhar | Targanta Therapeutics Corporation | |
| 2007 | Oral Direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deepveiin thrombosis or pulmonary embolism -11899 | Dr. Sudhindran | Bayer HealthCare |
| Oral Direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deepveiin thrombosis or pulmonary embolism -11702 | Dr. Sudhindran | Bayer HealthCare | |
| A Phase 3andomized Dauble blind parallel group multicentre placebo controlled study of INTRAVENOUS (IV) | Dr. Puneet Dhar | Progenics Pharmaceuticals | |
| A Multicenter, Randomized,Dauble blind,Placebo controlled, Dose ranging Study to assess the Efficacy and safety of TZP-101 when Administered as a 30 miniute I.v..Infusion for postoperative Lleus to Subjects Undergoing major Open AbdominalSurgery | Dr. Puneet Dhar | Tranzyme Pharma,Inc | |
| Gynacology | |||
| Year | Project Title | PI | Funding Agency |
| 2005 | Generation study | Dr. Rajammal | |
| Head & Neck | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | Identification, isolation and characterization of tumor initiating cells (TICS) from oral squamous cell carcinoma | Dr. Moni Abraham | ICMR Fellowship : Smt. Sindhu V G |
| UGC GRANT-Phd Students | Dr. Moni Abraham | UGC Fellowship: Smt. Priya S | |
| 2008 | Effect of Inhibition of Nuclear Factor kappa B (NFkB) using to PIcally Applied Curcumin on Split Skin Graft Survival in the Treatment of Chronic Wounds |
Dr. Subramania Iyer | Department Fund |
| Bowman Brik Inhibitor Concentrate and Oral Leukoplakia: A randomized Phase II b Trial | Dr. Moni Abraham | NIH | |
| 2007 | A randomized multicentre therapeutic confirmatory study to evaluate the efficacy and safety of proxinium plus best supportivecare versus best supportive care along in patients with advanced squamous cell carcinoma of the head & neck who have received atle | Dr. Moni Abraham | Viventia Biotech Inc |
| Proposal for Head & Neck Biorepository Service | Dr. Moni Abraham | Department Fund | |
| A Randomized Dauble Blind Placebo controlled Multicentre Phase III study of Post Operative Adjuvant5 Lapatinib or Placebo Monotherapy in high risk subjects with Resected Squomousw Cell Carcinoma of Head & Neck (SCCHN) | Dr. Subramania Iyer | GSK Glaxo SmithKline | |
| 2006 | Gene expression profiling of H&N squamous cell carcinoma by DNA microarray | Dr. Moni Abraham | CSIR |
| Lymphocintography for evaluation of nodal metastasin H&N | Dr. Moni Abraham | D.S.T.Kerala | |
| Assessment of Oral Self Examination for early detection of oral cancers and precancers in high risk rural population. | Dr. Moni Abraham | D.S.T.New Delhi | |
| Prevelance of Hypothyroidism following treatment of Head & Neck Cancer and its impact on quality life | Dr. Subramania Iyer | Head & Neck Research | |
| A phase II Randomized Opel Label Controlled Clinical Trial to evaluate safety & efficacy of WCK 771 in comparison with vancomycin or cefazolin in the treatment of complicated skins ,soft tissue,infections caused by Gram +ve bacteria | Dr. Subramania Iyer | Wockhardt Ltd | |
| 2005 | Curcumin Study-to evaluate the effect of curcumin | Dr. Moni Abraham | D.B.T.NewDelhi |
| Head&Neck Oncology SARD Programme | Dr. Moni Abraham | D.S.T.Kerala | |
| 2004 | SULINDAC Study | Dr. Moni Abraham | MSKC-centre-USA |
| Human Cytogenetic | |||
| Year | Project Title | PI | Funding Agency |
| 2006 | Chromosome 22911 microdetection in patients with selected Congenetial heart disease Study of Prevalence phenotype, Genotype and mode of inhaitance | Dr. M.V.Thampi | I.C.M.R |
| ISM | |||
| Year | Project Title | PI | Funding Agency |
| 2005 | I.S.M. Speciality Clinic of Yoga & Naturopathy | Dr. Prem Nair | ISM N.Delhi |
| ISM Ayurveda Panchakarma Unit | Dr. Prem Nair | ISM N.Delhi | |
| Medical Engineering | |||
| Year | Project Title | PI | Funding Agency |
| 2006 | Modeling the effects of decreesed levels of GABA & accumulation | Dr. S.N.Sarbadhikari | D.S.T.Kerala |
| Autonomous mobile Robots based on bioinspired artificial control | Dr. S.N.Sarbadhikari | D.S.T.New Delhi | |
| Medical Astrology | |||
| Year | Project Title | PI | Funding Agency |
| 2006 | Medical Astrology | Dr. Jaggu Swami | Surplus Fund |
| Metabolic Disorder | |||
| Year | Project Title | PI | Funding Agency |
| 2006 | Augmentation Project toMass Screening Programme for inborn Errors of Metabolism in Kerala (SARD) | Dr. Kannan Vaidhyanathan | Kerala state Council |
| 2004 | Newborn Mass screening programme for inborn errors of Metabolism in Kerala | Dr. Kannan Vaidhyanathan | D.S.T.Kerala |
| Microbiology | |||
| Year | Project Title | PI | Funding Agency |
| 2007 | Clinico-Epidemiologic and molecular Charactorization of Extended Spectrum Beta Lactamase Producing Klebsiella spp.E.col & Enterobacter spp causing Nosocomial and Community Infections | Dr. Kavitha R Dinesh | ICMR/CMC Vellore |
| Molecular Medicine | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | CSIR Junior Research Fellowship | Dr. T.S. Ganesan | CSIR |
| Ramalingaswami Fellowship | Dr. Raja Biswas | D.B.T.NewDelhi | |
| 2008 | Biology of Cancer Stem Cell | Dr. T.S. Ganesan | D.B.T.NewDelhi |
| Identification of novel cell surface molecules of threpeutic significance in central nervous system leukemia. | Dr. Krishna Kumar Menon | D.S.T.Kerala | |
| Nanosciences | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | Fellowship and other operational expence for M Tech Nanotechnology student | Dr. Shanti Nair | Tata Chemicals Ltd |
| UGC GRANT-Phd Students | Dr. Shanti Nair | UGC Fellowship: Smt. Aswathy J | |
| 2008 | Nano toxicology and Nano medicine | Dr. Shanti Nair | D.B.T.NewDelhi |
| Novel biodegradable Thermo- Responsive Nano- Vehicles for cancer Drug Delivery Applications | Dr. R. Jayakumar | D.B.T.NewDelhi | |
| Novel Nano delivery carrier for systemic control and release of parathyroid hormone for treatment of bone diseases | Dr. Nagarajan Selvamurugan | D.B.T.NewDelhi | |
| Self- tracking nano- delivery vehicle for siRNA based gene silencing | Dr. Manzoor K | D.B.T.NewDelhi | |
| Preparation of novel biogradable chitin scaffolds with hydroxya patite /zn0 nanoparticles for wound dressing applications | Dr. R. Jayakumar | D.S.T.New Delhi | |
| Financial assistance for the P.G Entrance (M. Tech, nano medical Science) | Dr. Shanti Nair | D.S.T.New Delhi | |
| Electro nanoprocessing of semiconductor nanotube arrays for high efficiency photovoltaics | Dr. Shanti Nair | D.S.T.New Delhi | |
| Preparation of Chitin Hydrogel and Carboxymethyl Chitin | Dr. Shanti Nair | India sea Food | |
| Preparations of Nano formulations | Dr. Shanti Nair | THEMIS Medicare | |
| 2007 | Processing Compatibilization and targeting of semiconductor nano crystals for cancer Diagonostics | Dr. Deepthy Menon | D.B.T.NewDelhi |
| 2006 | Nano Surface Bioengineering of Implants | Dr. Shanti Nair | D.B.T.NewDelhi |
| Implants tissue Engineering Stem cell research Nanotechnology | Dr. Shanti Nair | D.S.T.New Delhi | |
| Nephrology | |||
| Year | Project Title | PI | Funding Agency |
| 2008 | A sequential adaptive phase II/III multi centre,randomized dauble blind placebo controlled study to evaluate the efficacy and safety of Abatacept versus placebo on abackground of Mycophenolat Mofetil and Glucocorticosteroids in subjects with active prolif | Dr. George Kurian | Bristol Myers Squibb Pharmasuitical Research Institute |
| 2006 | A randomized dauble blind placebo-controlled four arm parallel group multicenter multinational safety and efficacy trial of 100 mg, 300 mg And 900 mg of Abetimus Sodium in systemic lupus erythematosus SLF patients with a history of renal disease | Dr. George Kurian | La jolla Pharmasuiticals |
| Extension of Investigational product(Aropotion) Expiry date for the clinical trial of recombinant Human Erythropoietin in patients with chromic renal failure | Dr. V.N.Unni | T S Corporation Korea | |
| Neurology | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | A Randomized Multicentre,Placebo-Controlled And Active Reference (Glatiramer Acetate) Comparison Study To Evaluate The Efficiancy And Safety Of BG00012 In Subjects With Relapsing- Remitting Multiple Scelerosis | Dr. Sruresh Kumar | Biogen IDEC |
| 2006 | PROFESS STUDY-prevention Regimen for Effectively avoiding second stroke. | Dr. Anand Kumar | Institute of population Health & clinical Research |
| VIATOPS STUDY-Clinical trial examining the efficacy and safety of Multivitamin theraphy in secondry stroke prevention | Dr. Vinayan | Johnson & Johnson | |
| TOPMAT STUDY-study to acess the safety and tolarability and efficacy of To piramates oral liquid and sprinkle formulation as an adjunct to concurrent Anticonvulsant theraphy for infants with refractory partial onset seizures with open label Extension |
Dr. N.V.Ahsan Moosa | Johnson & Johnson | |
| Molecular genitics analysis of Von Hippel Lindau Syndrome in Kerala State | Dr. Dilip Panikar | KSCSTE | |
| Neurosurgery | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | Efficacy and Safety of Apr 1 in Adult patients with recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) as compared to standard treatment with Temozolomide or BCNU: A randomized Actively controlled open label clinical phase III study | Dr. Dilip Panikar | Antisense Pharma |
| 2008 | A prospective, multicenter, double blind, randomised placebo controlled, parallel group to access the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality in adult patients with aneurismal subarachnoid hemorrh | Dr. Dilip Panikar | Actelion Pharmaceuticals ltd |
| 2006 | Open label Dose Confirmation Study of Interstitial 131 I-chTNT- I/B Mab (COTARAtm) for the treatment of Recurrent Glioblastoma Multiforme (GBM) | Dr. Dilip Panikar | Peregrine Pharmaceuticals |
| Nursing | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | To assess the nurse care rendered by student nurses as perceived by patients and staff nurses of Amrita Institute of Medical Sciences and Research Centre | Ms. Tintu Chandran (Nursing Student) | Internal (Department)/Funding Institutional |
| To assess the knowledge level regarding breast feeding practices among primigravida mothers | Ms. Jissy Varghese (Nursing Student) | Internal (Department)/Funding Institutional | |
| Oncology | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | Phase 1b single arm, open label, multicentre study of fluphenazine HCI monotherapy in relapsed or relapsed and refactory multiple myeloma | Dr. T.S. Ganesan | Immune Control Inc |
| Lenalidomide plus short course Dexamethasone treatment in Newly diagnosed Multiple Myeloma- A single Centre study. | Dr. Wesley M Jose | Internal (Department)/Funding Institutional | |
| AXITINIB (AG-013736) as Second Line Therapy for Metastatic Renal Cell Cancer: AXISTRIAL | Dr. K.Pavithran | Pfizer Limited | |
| A Phase III study of Vinflunine plus gemcitabine versus Paclitaxel plus gemcitabine n patients with unresectable, locally recurrent or Metastatic breast cancer after prior anthracycline- based adjuvant chemotherapy | Dr. Prasad Narayanan / Dr. K.Pavithran | Pierre Fabre Medicament Represented by Institute de Recherche Pierre Fabre | |
| 2008 | A phase 4 , parallel group,Multi-Centre study to Asses the safety and Efficacy of Multiple dosing Regimens of IV Conivaptan in subjects with Euvolemic or Hypervolemic Hyponatremia | Dr. Pavithran | Astellas Pharma US Inc. (APUS) |
| An open Label ,Dose Finding,Prospective Multicenter,Randomized Parallel group study to asses the efficacy and safety of three different dose levels of AV1-014(G-CSF) compared with a standard dose of Neupogen in brest cancer patients at high(>20%) risk for | Dr. T.S. Ganesan | AviGenics,Inc | |
| Immunoscintigraphy to Assess uptake of 99 TCM Labeled CD 105 antibody in Patients with Solid Tumors | Dr. T.S. Ganesan | Board of Research in Nuclear Sciences (BRNS) | |
| A phase III study of Erbbr2 positive advanced or metastatic gastric or esophageal or gastroesophageal junction adenocacinona treated with capecitabine plus oxaliplatin with or without lepatinib | Dr. T.S. Ganesan | Glaxo Smithkline | |
| A dauble blind Randomized Phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with paclitaxel in patients with locally recurrent or Metastatic Brest Cancer | Dr. Prasad Narayanan | Reliance clinical Research sevice | |
| A Multinational, Randomised ,Double Blind,Placebo Controlled study to evacuate the efficiancy and safety of AVE5026 in the prevention of venous Thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing Chemotherapy | Dr. K.Pavithran | Sanofi Aventis Research & Devolopment | |
| PCR screening and genetic counselling for female carriers of common molecular mutations of Hemophilia A and expanded diagnostic testing for hemophilia A in India | Dr. K.Pavithran/Dr.Manoj Unni | Source of fund not specified | |
| 2007 | A Randomized Double blind Multicentre study of Denosumab Compared with Zoledronic Acid(Zometa ) in the treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer | Dr. Pavithran | Amgen Inc |
| Clinical Research Training Centre | Dr. T.S. Ganesan | D.B.T.NewDelhi | |
| A randomized Phase 3 Study of Pemetrexed in combination with Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head& Neck Cancer | Dr. Pavithran | Eli Lilly & Company | |
| Study of the safety and efficacy of the intravenous and oral formulation of Nuerokinin-1 receptor antagonist Casopitant (GW69769) in combination with ZOFRAN and Dexamethasone for the prevention of chemotharapy induced nausea and vomitting in cancer patien | Dr. Pavithran | Glaxo Smithkline | |
| Patterns of care and Survival studies in Head & Neck Cancer Cancer Cervix,Cancer breast( All India study) | Dr. T.S. Ganesan | National Cancer Registry Project – ICMR | |
| Phase II study of Intra peritoneal chemotherapy in patients with ovarian cancer | Dr. T.S. Ganesan / Dr. Abdul Majeedh | Ph.D student | |
| Immunoscintigraphy to assess uptake of 99 TcM labled CD 105 antibody in patients with solid Tumors | Dr. Ganeshan/ Dr.Kishore Kumar | Ph.D student | |
| 2006 | Open Label Randomized Phase II Study of two Different Dosing Regimens of Capecitabine in combination with intravenous Docetaxel (Q3W) in patients with locally Advanced and /or Metastatic Brest Cancer | Dr. Pavithran | Hoffmann-La Roche Inc |
| A Phase I/II Open label Dose Escalation Study to Determine the safety Tolerance and Preliminary Activity of Intravenous High-Dose Fluphenazine HCI in patients with Advanced Multiple Mycloma | Dr. T.S. Ganesan | Immune Control Inc | |
| Study of Epocitin Alfa plus standard supportive care verses standard supportive care in Anemic Patients with Metastastatic Breast cancer receiving First-line standard chemotheraphy | Dr. Pavithran | Johnson & Johnson | |
| paclitaxel/carboplatin plus pf-3512676 verses paclitaxel /carboplatin as first live treatment of patients | Dr. K.Pavithran | Pfizer Limited | |
| Comparison of Thalidomide versus high dose Dexamethasone for the treatment of relasped refractory multiple Myloma (THAPHINT) | Dr. Pavithran | Reliance clinical Research service | |
| The study safety and efficacy of Recombinant Granulocyte Colony Stimulating Factor-rG-CSF (ReliGrast TM ) in patients with Chemotherapy induced neutropenia | Dr. Pavithran | Reliance Life Sciences Pvt.Ltd | |
| Prostate cancer screening in Kerala | Dr. Chitradara | Science & Technology | |
| 2005 | Randomised phase 3 trial of ALTIMA and cisplatin versus GEMZAR and cisplatin inpatients with locally advanced. | Dr. Pavithran | Johnson & Johnson |
| NYU-Brest Cancer Project | Dr. Vijayakumar | Newyork University | |
| Opthalmology | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | A Phase 3 safety and Efficacy Study of Vitreosolve for three ophthalmic Intravitreal injections for inducing Posterior Vitreous Detachment in Retinopathy Subjects | Dr. Gopal S PIllai | Vitreoretinal Technologies, Inc |
| 2008 | A 6 day ,Phase 3, Multicentre,Randomized,Double Masked Parallel study to compare the safety and efficacy of Gatifloxacin 0.5% opthalmic solution BID with that of Vehicle in the treatment of Acute Bacterial Conjunctivitis | Dr. Meenakshi Dhar | ALLERGAN Pharmacutical Development Center (India) Pvt Ltd |
| Catract operation/ Diabetic retinopathy treatment / Gloucoma management / low vision services | Dr. Prem Nair | National Programme For Control Of Blindness Directorate General Of Health Services | |
| Multicentre open label study evaluating the efficacy and safety of e PInastine Hydrocloride 0.05/opthalmic solution used twice daily for 3 weeks in adult patients with seasonal allergic conjunctants. |
Dr. Meenakshi Dhar | ALLERGAN Pharmacutical Development Center (India) Pvt Ltd | |
| Paediatric Cardiology | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | Development of an epidemiological model to modify cadiovascular risk profile in children | Dr. R Krishna Kumar | I.C.M.R |
| 2007 | Establishment of Nodal coordinating center for training of Satelite Centers for Establishment of the RF/RHD registry (Wayanad,Mumbai and potentially Chatisgrah) | Dr. Krishna Kumar | I.C.M.R |
| 2006 | Rheumatic fever/Rheart disease (RF/RHD) registry at Wynad | Dr. R Krishna Kumar | I.C.M.R |
| Creation & evaluation of a clinical stragey to screen for contingental heart disease in newborn | Dr. R Krishna Kumar | I.C.M.R | |
| Study to acess safety of oral Sildenafil in the treatment of subjects protocol A1481156 | Dr. R.Krishnakumar | Pfizer Limited | |
| TTK Chitra Heart Valves | Dr. Krishna Kumar | T.T.K.Healthcare Ltd | |
| 2005 | Nutritional recovery after corrective surgery for congenital Heart disease in children | Dr. R.Krishnakumar | D.S.T.Kerala |
| 2004 | Randamised control trial of Sildenafil for Peadiatric Pulmonary hypertension | Dr. R.Krishnakumar | Pfizer Limited |
| Paediatrics / Cardiology | |||
| Year | Project Title | PI | Funding Agency |
| 2007 | Losartan/HCTZ combination as compared to Losartan Monotherapy in Peadiatric Patients with essential Hypertension study | Dr. Edwin Francis | MSD Pharmasuiticals |
| Paediatrics / Cardiology | |||
| Year | Project Title | PI | Funding Agency |
| 2007 | Losartan/HCTZ combination as compared to Losartan Monotherapy in Peadiatric Patients with essential Hypertension study | Dr. Edwin Francis | MSD Pharmasuiticals |
| Peadiatric CVTS | |||
| Year | Project Title | PI | Funding Agency |
| 2007 | International randomized double blind clinical study evaluating the efficacy and safety of Clopidogrel 0.2 mg/kg once daily versus placebo in neonates and infants withcyanotice congenital heart disease palliated with a systemic-to-pulmonary artery shunt. | Dr. Suresh G Rao | Sanofi Aventis Research & Devolopment |
| Physiology | |||
| Year | Project Title | PI | Funding Agency |
| 2008 | Correlation between Anthropometric measurements and peak xepiratory flow rate in adolescent age group | Vinaya Vijayan | No Funding Required |
| Psychiatry | |||
| Year | Project Title | PI | Funding Agency |
| 2008 | Rejection sensitivity : lLinking attachment pattern to psycho social adjustment in eary adoloscence | Dr. Gitanjali | Self |
| Effect of a computer aidid cognitive enrichment programme on the scolastic perfomance of children | Dr. Aniita Rajah | Self | |
| Pulmonary | |||
| Year | Project Title | PI | Funding Agency |
| 2009 | Comparison of clinical scoring system and overnight polusomnography in diagnosis of obstructive sleep apnea- a comparative study | Dr. Varun Patel (DNB Student) | Internal (Department)/Funding Institutional |
| 2008 | A Randomized,4 week ,placebo controlled, dauble blind, 6 arm parallel group dose finding clinical trial to assess the efficacy safety and pharmacokinetics of three different doses of formoterol (6,12 &19ug) combined with the inhaled anticholinergic aclidi | Dr. Dharshana Vishwam | COVANCE |
| A randomized dauble blind parallel study of a once daily dosing of EPI-12323 versus placebo in symptomatic moderate to severe Asthematics on Low-Dose inhaled corticosteriods and long-acting Agonists | Dr. Kumari Indhira | Epigenesis Pharmaceuticals | |
| Urology | |||
| Year | Project Title | PI | Funding Agency |
| 2008 | A Multicentre, Double blind, Placebo, Controlled, Parallel group, Study to explore the Dose Dependent Response to three levels of BOTOX® Botulinum Toxin Type A Purified Neurotoxin complex followed by an open label extension phase in patients with urinary | Dr. Georgie Mathew | ALLERGAN Pharmacutical Development Center (India) Pvt Ltd |
| A phase III Randomized placebocontrolled dauble blind study to Assess the efficacy and safety of once daily orally administeredZD4054 10 mg in non metastatic hormone resistant prostate Cancer Patients | Dr. Ginil Kumar | Astra Zeneca | |
| A phase II b/III, Multicentre,dauble blind,randomized placebocontrolled dose ranging study of Transulosin Hydrochloride (Low medium and high dose) as treatment in children with Nueropathic Bladder for three months | Dr. Georgie Mathew | SIRO Clinpharm Pvt Ltd | |
| 2006 | Prospectius multicentre active and placebo controlled randomised Dauble blind Phase II study | Dr. Georgie Mathew | Salvat S.A Laboratom |